and their statistical basis; i.e., how will these data be extrapolated to the population. 2. We know that dementia has many causes and at lease several coexist in most patients. Also the pathologic basis for these diseases begins perhaps decades before symptom onset. Please provide a clearer estimate of how you will assess whether silent disease is present. 3. The ADNI 3 protocol mentioned in the paper includes both CSF assays and PET scans, are there any plans to do do either? Please explain. 4. Two-stage screening is often inefficient and limits observation of due to only partial testing at time of screening events; based on the predictive values of the tests applied. When only multiple "screens" are applied in early cognitive impairment this leads to somewhat fragmented approach of data collection among the screen negatives (normals) where such detailed data could be most valuable at detecting small initial changes or beginnings of a declining trajectory --whereas the screen may not be sufficiently sensitive by itself. Thus in a sample as small as 3000 it would seem to be preferable to provide a common exam protocol for all rather than to implement a two stage design.
VERSION 1 -AUTHOR RESPONSE
Response to the Reviewers Reviewer: 1 Reviewer Name: Antony Bayer Institution and Country: Cardiff University, Wales, UK Please state any competing interests or state 'None declared': None This is an important cohort study, but unfortunately the manuscript lacks the detail characteristic of a protocol and instead provides more of a broad overview of what is proposed.
Thanks for your thoughtful review. We added the detailed characteristics of our protocol in the revised manuscript.
The abstract does not provide any detail on the "rich" data to be collected, nor what the study adds to the cognitive health data that will be available already in LASI. The strengths and limitations section is more informative, though the only limitation given is that only 14 of the 36 Indian states and Union Territories will be covered, raising a question about whether the study with truly provide populationrepresentative data, as stated.
We provide details explaining the additional cognition data that LASI-DAD collects in comparison to the main LASI. The selected 14 states represent 72% of the population, and to obtain population representativeness, we post-stratify our sample based on the Census data.
In general, the information provided is imprecise or important detail is missing -for example, how the sample will be "randomly" drawn from those with high and low risk, how respondents will be recruited and what happens if a potential respondent does not consent, what training the field team administering HCAP receives, how a representative sample for the 200 imaging and 960 genotyping studies will be chosen, dates of data-collection, plans for data management and oversight, etc.
Diagnosis will be based on Clinical Dementia Rating but this is based on a standardised interview and no mention is made that this is happening?
We provide the details aforementioned by reviewer 1.
Reviewer: 2
Reviewer Name: Walter Kukull Institution and Country: University of Washington, Seattle, Washington, USA Please state any competing interests or state 'None declared': none Thank you for the opportunity to review this well written protocol. I have only a few minor comments.
1.
The sampling scheme could be more clearly stated along with the sampling frame and the potential generalizability of projections and their statistical basis; i.e., how will these data be extrapolated to the population.
In the revised manuscript, we provide additional details of the sampling scheme and the potential generalizability of the projections, as well as their statistical basis.
2.
We know that dementia has many causes and at lease several coexist in most patients. Also the pathologic basis for these diseases begins perhaps decades before symptom onset. Please provide a clearer estimate of how you will assess whether silent disease is present.
For a sub-sample, we plan to obtain brain imaging data, from which we plan to provide additional information on a pathologic basis. However, these data are limited to a sub-sample, and we will address this as a limitation.
3.
The ADNI 3 protocol mentioned in the paper includes both CSF assays and PET scans, are there any plans to do do either? Please explain.
Our current protocol does not include CSF assay or PET scans. As noted, we proposed to implement the brain imaging study on a pilot basis, limited to structural MRIs and resting state functional MRIs.
4.
Two-stage screening is often inefficient and limits observation of due to only partial testing at time of screening events; based on the predictive values of the tests applied. When only multiple "screens" are applied in early cognitive impairment this leads to somewhat fragmented approach of data collection among the screen negatives (normals) where such detailed data could be most valuable at detecting small initial changes or beginnings of a declining trajectory --whereas the screen may not be sufficiently sensitive by itself. Thus in a sample as small as 3000 it would seem to be preferable to provide a common exam protocol for all rather than to implement a two stage design.
We provide a common exam protocol for the entire LASI-DAD study sample of 3,000. The main LASI study sample included a cognition module, which provided the basis for our sampling strategy. We provided further discussion on the sampling strategy, and we also provided a comparison table with LASI and LASI-DAD cognitive tests in the revised manuscript.
VERSION 2 -REVIEW

REVIEWER
Walter A. Kukull University of Washington, Dept oi Epidemiology, Seattle WA, USA REVIEW RETURNED 14-Jun-2019
GENERAL COMMENTS
The reviewer completed the checklist but made no further comments.
